###begin article-title 0
Tolerance to the Neuron-Specific Paraneoplastic HuD Antigen
###end article-title 0
###begin p 1
Conceived and designed the experiments: ID NEB BS RBD. Performed the experiments: ID NEB. Analyzed the data: ID NEB BS RBD. Contributed reagents/materials/analysis tools: BS. Wrote the paper: ID RBD.
###end p 1
###begin p 2
###xml 912 920 912 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1033 1041 1033 1041 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1140 1147 1140 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 811 816 <span type="species:ncbi:10090">mouse</span>
###xml 1006 1010 <span type="species:ncbi:10090">mice</span>
Experiments dating back to the 1940's have led to the hypothesis that the brain is an immunologically privileged site, shielding its antigens from immune recognition. The paraneoplastic Hu syndrome provides a powerful paradigm for addressing this hypothesis; it is believed to develop because small cell lung cancers (SCLC) express the neuron-specific Hu protein. This leads to an Hu-specific tumor immune response that can develop into an autoimmune attack against neurons, presumably when immune privilege in the brain is breached. Interestingly, all SCLC express the onconeural HuD antigen, and clinically useful tumor immune responses can be detected in up to 20% of patients, yet the paraneoplastic neurologic syndrome is extremely rare. We found that HuD-specific CD8+ T cells are normally present in the mouse T cell repertoire, but are not expanded upon immunization, although they can be detected after in vitro expansion. In contrast, HuD-specific T cells could be directly activated in HuD null mice, without the need for in vitro expansion. Taken together, these results demonstrate robust tolerance to the neuronal HuD antigen in vivo, and suggest a re-evaluation of the current concept of immune privilege in the brain.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 291 294 291 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Medawar1">[1]</xref>
###xml 296 299 296 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Galea1">[2]</xref>
###xml 566 569 566 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Carson1">[3]</xref>
###xml 571 574 571 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Hickey1">[4]</xref>
###xml 797 800 797 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Galea2">[5]</xref>
###xml 905 908 905 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Galea1">[2]</xref>
###xml 1120 1123 1120 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-HarlingBerg1">[6]</xref>
###xml 1125 1128 1125 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-HarlingBerg2">[7]</xref>
Immune tolerance to self antigens is believed to protect against autoimmunity, but not in the central nervous system (CNS), which has been widely accepted to be an immune privileged site since Medawar discovered that transplanted allografts were rejected in the body but survived in the CNS [1], [2]. This idea was reinforced when it was recognized that the blood-brain barrier, the absence of lymphatics in the CNS, and the expression of immunosuppressive cytokines and death receptors all serve to protect the brain from potentially harmful inflammatory responses [3], [4]. The mechanisms that might underlie CNS immune privilege have been periodically redefined as new ways of maintaining tolerance have been discovered, and as it has been recognized that CD8+ T cells can infiltrate the brain [5], but the idea remains that the immune system is restricted from seeing brain specific cellular antigens [2]. Although soluble brain antigens readily gain access to the draining cervical lymph nodes where they are taken up by antigen presenting cells, no such pathway has been defined for cellularly-restricted proteins [6], [7]. The immune system, it would seem, is ignorant of antigens sequestered within neurons, providing an explanation of how the brain is protected from potentially damaging autoimmune disease.
###end p 4
###begin p 5
###xml 630 633 630 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Graus1">[8]</xref>
###xml 635 638 635 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Dalmau1">[9]</xref>
###xml 905 909 905 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Dalmau2">[10]</xref>
###xml 910 914 910 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Jaeckle1">[12]</xref>
###xml 1160 1164 1160 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Darnell1">[13]</xref>
###xml 1328 1332 1328 1332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Manley1">[11]</xref>
###xml 1431 1435 1431 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Darnell2">[14]</xref>
###xml 159 167 <span type="species:ncbi:9606">patients</span>
###xml 317 325 <span type="species:ncbi:9606">patients</span>
###xml 407 415 <span type="species:ncbi:9606">patients</span>
###xml 506 514 <span type="species:ncbi:9606">patients</span>
###xml 775 783 <span type="species:ncbi:9606">patients</span>
###xml 1344 1352 <span type="species:ncbi:9606">patients</span>
The paraneoplastic neurologic diseases (PND) provide an important model of immunity to brain-specific antigens. For example in the Hu paraneoplastic syndrome, patients experience neurologic symptoms that may affect the dorsal root ganglia, limbic system, cerebellum, and brainstem. The neurologic symptoms develop in patients who have small cell lung cancer (SCLC), tumors that express the HuD antigen, and patients generate impressive tumor immunity to this otherwise aggressive malignancy. SCLCs from Hu patients are usually limited to single nodules, and are typically discovered only after presentation of neurologic symptoms [8], [9]. A link between the neurologic symptoms and tumor immunity in the disorder was made by Posner and colleagues, who discovered that these patients harbor high titer antibodies to HuD, a normally neuron-specific RNA binding protein that is also expressed by SCLC cells [10]-[12]. A general model for the disorder has been that the normally neuron-specific expression of the HuD antigen, combined with immune privilege in the brain, accounts for the immunogenicity of the HuD antigen when it is ectopically expressed in SCLC [13]. However, the nature of such immune privilege is poorly understood, and may not explain all aspects of the disorder. For example, even though all SCLC express HuD [11], only some patients make an immune response to the tumor (20%), and very few go on to develop PND [14], as diagnosed clinically and confirmed by the presence of high titer anti-HuD antibodies in the serum and cerebrospinal fluid. While these observations suggest the possibility that there may be mechanisms responsible for inhibiting autoimmunity to HuD, they would also conflict with the idea of immune privilege to neuron-restricted antigens.
###end p 5
###begin p 6
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Darnell1">[13]</xref>
###xml 434 435 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 470 474 470 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Benyahia1">[15]</xref>
###xml 476 480 476 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Jean1">[16]</xref>
###xml 816 820 816 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Santomasso1">[17]</xref>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Albert1">[18]</xref>
###xml 998 1002 998 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-deBeukelaar1">[19]</xref>
###xml 1095 1099 1095 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Plonquet1">[20]</xref>
###xml 1100 1104 1100 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Tanaka1">[22]</xref>
###xml 1142 1146 1142 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Roberts1">[23]</xref>
###xml 1331 1338 1331 1338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
###xml 890 898 <span type="species:ncbi:9606">patients</span>
###xml 1086 1094 <span type="species:ncbi:9606">patients</span>
###xml 1249 1254 <span type="species:ncbi:10090">mouse</span>
The presence of antibodies to Hu in the blood and cerebrospinal fluid are important diagnostic markers for the disorder. However several observations have suggested a T cell mediated component to the PNDs [13]. The Hu proteins are sequestered intracellularly within neurons, activated T cells are present in the cerebrospinal fluid of Hu patients, and the immune response in patients is Th1-skewed, with Th1 CD4 helper T cells and IgG1 antibodies present in circulation [15], [16]. All attempts to create mouse models of the disease by immunizing with whole HuD protein have failed to induce neuronal degeneration despite the generation of high titer antibodies to Hu. Moreover, CD8 T cells have been shown to play an important role in the pathogenesis of another form of PND, paraneoplastic cerebellar degeneration [17], [18]. Nonetheless, efforts to identify HuD-specific T cells in SCLC patients with the Hu syndrome have yielded mixed results. Some investigators have reported negative results [19], while others have found inconsistent evidence for such cells specific to affected patients [20]-[22], or the presence of atypical T cells [23]. To examine the nature of the immune response to HuD, we have studied HuD-specific CD8 T cells in the mouse, and found that there is normally robust tolerance to this neuronal protein in vivo.
###end p 6
###begin title 7
Materials and Methods
###end title 7
###begin title 8
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 8
###begin p 9
###xml 26 29 26 29 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 100 103 100 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 109 113 109 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Akamatsu1">[24]</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
Wild type C57BL/6 and Rag1-/- (stock no. 00216) mice were purchased from The Jackson Laboratory. HuD-/- mice [24] (7x backcrossed onto the C57BL/6 background) were obtained from H. Okano.
###end p 9
###begin title 10
Ethics Statement
###end title 10
###begin p 11
All animals were handled in accordance with animal husbandry guidelines established and reviewed by the Rockefeller University Institutional Animal Care and Use Committee (IACUC), which complies with federal and state regulations that concern the use of experimental animals.
###end p 11
###begin title 12
HuD Peptide Screen
###end title 12
###begin p 13
###xml 297 298 293 294 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 365 366 361 362 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 8 12 <span type="species:ncbi:10090">mice</span>
C57BL/6 mice were injected in the right footpad with 125 ug of a single HuD peptide emulsified in TiterMax adjuvant. On day 7, CD8+ T cells were isolated from the right popliteal and inguinal lymph nodes by MACS purification (Miltenyi Biotec) and plated in a 20 hour IFNgamma ELISPOT assay at 2x105 CD8+ T cells per well. EL4 cells were added as stimulators at 5x104 per well with 10 uM peptide.
###end p 13
###begin title 14
Immunizations
###end title 14
###begin p 15
###xml 113 114 113 114 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
For immunization with recombinant adenovirus, 6-8 week old mice were injected with 100 ul purified adenovirus (109 PFU/mL) i.d. and treated with Pertussis Toxin (Sigma) at days 0 and 2. For immunization with influenza virus, 6-8 week old C57BL/6 mice were injected i.p. with 300 H.A.U. of influenza A/PR/8.
###end p 15
###begin title 16
###xml 23 29 <span type="species:ncbi:10090">murine</span>
Preparation of primary murine kidney cells
###end title 16
###begin p 17
###xml 370 371 366 367 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9</sup>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 273 278 <span type="species:ncbi:10090">mouse</span>
Kidney cells from adult mice in single cell suspension were plated in 10 cm dishes in D-10 (DMEM supplemented with 10% FBS, nonessential amino acids, sodium pyruvate, glutamine, 22-ME, gentamicin). Cultures were fed by replacing D-10 on days 4 and 7. On day 7, recombinant mouse IFNgamma (R & D Systems) was added at 10 U/mL. On day 8, 10 ul recombinant adenovirus at 109 PFU/mL was added the cells were harvested on day 9 for use in an IFNgamma Elispot assay.
###end p 17
###begin title 18
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse CD8+ T cell stimulation
###end title 18
###begin p 19
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 274 275 268 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 74 78 <span type="species:ncbi:10090">mice</span>
###xml 365 370 <span type="species:ncbi:9606">human</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
For in vitro stimulation, 2.5-3x107 splenocytes from adenovirus-immunized mice were incubated at 37degreesC in upright T25 culture flasks (Corning) in R-10 with 0.5 uM peptide for 7 days. For further rounds of restimulation, splenocytes were plated in 24 well plates (2-6x105 splenocytes per well) with peptide-pulsed feeder cells in R-10 with 50 CU/mL recombinant human IL-2 (Chiron). Feeder cells were prepared from spleens of naive syngeneic mice by pulsing with 0.5 uM peptide for 1 hour at room temperature and irradiating at 3,000 Rads before plating.
###end p 19
###begin title 20
Adoptive transfer
###end title 20
###begin p 21
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 598 599 598 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 35 39 <span type="species:ncbi:10090">mice</span>
###xml 119 124 <span type="species:ncbi:10090">mouse</span>
###xml 164 169 <span type="species:ncbi:10090">mouse</span>
###xml 211 216 <span type="species:ncbi:10090">mouse</span>
###xml 266 271 <span type="species:ncbi:10090">mouse</span>
For adoptive transfer experiments, mice received i.v. injections of 7 day in vitro stimulated CD8+ T cells (5x106 CD8+/mouse) and DCs pulsed with peptide (2x106 DC/mouse) along with IL-2 (6 injections of 105 CU/mouse i.p. every 12 hours) and Pertussis Toxin (400 ng/mouse i.p. on days 0 and 2). CD8+ cells were isolated from stimulation cultures by negative selection using a CD8+ T cell isolation kit (Miltenyi Biotec). Mature DCs were pulsed with 100 uM peptide in R-10 and incubated at room temperature for 1 hour, shaking every 15 minutes. The cells were then washed twice and resuspended at 107/mL in RPMI 1640 for i.v. injection.
###end p 21
###begin title 22
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse DC preparation
###end title 22
###begin p 23
###xml 62 66 62 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Inaba1">[25]</xref>
###xml 133 138 <span type="species:ncbi:10090">mouse</span>
Bone marrow-derived DCs were prepared as previously described [25]. On day 7, DCs were matured for 2 days with 125 ng/mL recombinant mouse TNFalpha (R&D Systems).
###end p 23
###begin title 24
Tetramer staining
###end title 24
###begin p 25
Data using surface antibodies (Becton Dickinson) and PE-labeled tetramers (Immunomics iTAg MHC Tetramer, Beckman Coulter) was acquired with a FACScaliber (Becton Dickonson).
###end p 25
###begin title 26
In Vivo CTL assay
###end title 26
###begin p 27
###xml 165 167 165 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 223 225 223 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 423 424 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 429 431 426 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 438 439 435 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 444 446 441 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 536 538 533 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 550 552 547 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 372 376 <span type="species:ncbi:10090">Mice</span>
Mice received a single i.v. injection of target cells. Targets consisted of two peptide-pulsed populations of CFSE-labeled syngeneic splenocytes in a 1:1 ratio: CFSElo syngeneic splenocytes labeled with 0.5 uM CFSE and CFSEhi syngeneic splenocytes labeled with 5 uM CFSE. One population was pulsed with 10 uM HuD p321 peptide and the other with 10 uM betagal p96 peptide. Mice received a single i.v. injection of 200 ul (107 CFSElo and 107 CFSEhi targets). 7 hours after target injection, the spleens were removed and the amount of CFSElo versus CFSEhi targets was quantitated by flow cytometry.
###end p 27
###begin title 28
Elispot assay
###end title 28
###begin p 29
###xml 66 70 <span type="species:ncbi:10090">mice</span>
CD8+ cells were isolated from spleens or lymph nodes of immunized mice using MACS purification (Miltenyi Biotec). T cells were added to IFNgamma ELISPOT plates at the indicated concentrations along with stimulators and incubated for 20 hours. Cells were washed out of the ELISPOT plate using a mild detergent followed by incubation with 1 ug/mL biotin-conjugated anti-IFNgamma mAb. Wells were developed using the Vectastain Elite Kit according to the manufacturer's instructions (Vector Laboratories). The ELISPOT plate evaluation was performed by an independent evaluation service (Zellnet Consulting) using an automated ELISPOT reader (Carl Zeiss).
###end p 29
###begin title 30
RMA/S Assay
###end title 30
###begin p 31
###xml 64 68 64 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Dyall1">[26]</xref>
RMA/S stabilization assay was performed as previously described [26].
###end p 31
###begin title 32
Results
###end title 32
###begin title 33
###xml 43 48 <span type="species:ncbi:10090">mouse</span>
Comprehensive screen to identify potential mouse H-2b HuD epitopes
###end title 33
###begin p 34
###xml 75 76 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 389 390 389 390 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 696 702 692 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g001">Fig 1a</xref>
###xml 771 777 767 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g001">Fig 1b</xref>
###xml 66 71 <span type="species:ncbi:10090">mouse</span>
###xml 170 174 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
To determine if HuD-specific CD8 T cells could be detected in the mouse H-2b repertoire, we performed a comprehensive screen of the entire HuD peptide library in C57BL/6 mice. The HuD peptide library consisted of 386 overlapping nonamers, including peptides derived from all known splice variants of the protein. To ensure that all HuD peptide-specific CD8 T cell clones present in the H-2b repertoire could expand, mice were immunized subcutaneously in the footpad with each individual HuD peptide emulsified in TiterMax adjuvant. CD8 T cells isolated from the draining lymph nodes were assessed for their ability to secrete IFNgamma in response to cognate peptide-pulsed syngeneic stimulators (Fig 1a). These experiments identified 7 potential HuD CD8 T cell epitopes (Fig 1b).
###end p 34
###begin title 35
p321 is the immunodominant CD8+ T cell epitope of HuD.
###end title 35
###begin p 36
###xml 280 281 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 356 357 352 353 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 748 756 744 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 908 909 901 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 992 993 985 986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1211 1219 1200 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1292 1300 1278 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 88 92 <span type="species:ncbi:10090">mice</span>
###xml 529 533 <span type="species:ncbi:10090">mice</span>
###xml 646 650 <span type="species:ncbi:10090">mice</span>
###xml 1237 1241 <span type="species:ncbi:10090">mice</span>
(a) A representative peptide screen of 16 HuD peptides. Individual or duplicate C57BL/6 mice were immunized with a single HuD peptide emulsified in TiterMax adjuvant. 7 days later, CD8+ T cells were harvested from draining lymph nodes and plated in an IFNgamma ELISPOT assay (2x105/well) with EL4 cells pulsed with 10 uM cognate or irrelevant peptide (5x104/well). The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean. Positive peptides were re-screened in triplicate mice. (b) 7 peptides (in bold) were identified as potential CD8+ epitopes from the HuD protein sequence. (c) C57BL/6 mice were immunized with AdVHuD plus PTx. 13 days after immunization, splenocytes were divided into 8 in vitro stimulation cultures and stimulated with each of the 7 HuD peptides or betagal p96. CD8+ T cells were purified from stimulation cultures and plated (104 T cells/well) with cognate or irrelevant peptide-pulsed irradiated EL4 cells (5x104/well) in an IFNgamma ELISPOT assay. The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean. Data is representative of three experiments. (d) As a control for in vitro priming, C57BL/6 mice were immunized with AdVbetagal+PTx and stimulated in vitro with each of the 7 potential HuD epitopes or betagal p96 and assayed for IFNgamma secretion as in (c).
###end p 36
###begin title 37
Identification of the immunodominant H-2b HuD epitope
###end title 37
###begin p 38
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 331 339 331 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 510 516 506 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g001">Fig 1c</xref>
###xml 569 577 565 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 707 713 696 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g001">Fig 1d</xref>
###xml 880 888 869 877 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 92 96 <span type="species:ncbi:10090">Mice</span>
###xml 647 651 <span type="species:ncbi:10090">mice</span>
We sought to identify immunodominant CD8 T cell epitopes from the 7 candidate HuD peptides. Mice were immunized with replication-deficient recombinant adenovirus expressing full length HuD to allow for in vivo processing and presentation of HuD peptides onto MHC I molecules, and splenocytes from immunized animals were stimulated in vitro for 7 days with each peptide. Of the 7 potential HuD epitopes, peptides 296 and 321 were able to prime CD8 T cells to secrete IFNgamma after adenovirus-HuD immunization (Fig 1c). These CD8 T cell responses were not the result of in vitro priming, since HuD peptides failed to elicit IFNgamma secretion from mice immunized with a control antigen (adenovirus-beta-gal; Fig 1d). Subsequent assays comparing HuD p296-specific and p321-specific CD8 T cells indicated that p296-specific CD8 T cells are low affinity cells, difficult to propagate in vitro, whereas p321-specific CD8 T cells can be reproducible and stably maintained in culture (data not shown), and we therefore focused on the latter.
###end p 38
###begin title 39
Characterization of HuDp321-specific CD8 T cells
###end title 39
###begin p 40
###xml 136 143 136 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 180 185 180 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig 2</xref>
###xml 188 196 188 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 625 628 625 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 776 779 776 779 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 786 792 786 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig 2a</xref>
###xml 814 820 814 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig 2b</xref>
###xml 944 947 944 947 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 978 985 978 985 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1232 1240 1232 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1328 1335 1328 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 589 593 <span type="species:ncbi:10090">mice</span>
###xml 613 617 <span type="species:ncbi:10090">mice</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
###xml 780 784 <span type="species:ncbi:10090">mice</span>
###xml 808 812 <span type="species:ncbi:10090">mice</span>
###xml 948 952 <span type="species:ncbi:10090">mice</span>
###xml 1158 1162 <span type="species:ncbi:10090">mice</span>
In order to assess whether HuD p321-specific CD8 T cells were able to lyse target cells in an antigen dependent manner, we performed an in vivo cytotoxic T lymphocyte (CTL) assay (Fig 2). In vitro stimulated HuD p321-specific CD8 T cells were adoptively transferred intravenously into a syngeneic host and assessed for their ability to lyse a population of peptide-pulsed target cells. In order to enhance the effector function of our transferred T cells, we co-injected mature C57BL/6 dendritic cells (DC) pulsed with p321 into hosts. We assessed target lysis in two different strains of mice: wild type C57BL/6 mice and Rag-/- mice. Transferred HuD-specific CD8 T cells were potent cytotoxic effectors in both strains, exhibiting 88% and 74% specific lysis of targets in Rag-/- mice (Fig 2a) and wild type mice (Fig 2b), respectively. Adoptive transfer of HuD p321-specific CD8 T cells together with DC pulsed with irrelevant peptide into Rag-/- mice yielded a lower level of in vivo cytotoxicity (20%; data not shown), suggesting that the DC pulsed with p321 served to expand the adoptively transferred population of HuD specific CD8 T cells in recipient mice. These results demonstrate that after activation by immunization and in vitro stimulation, HuD p321-specific CD8 T cells are able to function as cytotoxic effectors in vivo.
###end p 40
###begin title 41
Characterization of HuD p321-specific CD8+ T.
###end title 41
###begin p 42
###xml 8 9 8 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 28 36 28 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 123 124 123 124 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 298 300 298 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hi</sup>
###xml 322 324 319 321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lo</sup>
###xml 496 503 493 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 837 838 834 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 841 842 838 839 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 870 871 867 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 874 875 871 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 992 993 982 983 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1079 1080 1066 1067 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1446 1453 1433 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1559 1567 1546 1554 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1661 1669 1648 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 154 158 <span type="species:ncbi:10090">Mice</span>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 343 348 <span type="species:ncbi:10090">mouse</span>
###xml 540 545 <span type="species:ncbi:10090">mouse</span>
###xml 611 615 <span type="species:ncbi:10090">mice</span>
###xml 733 738 <span type="species:ncbi:10090">mouse</span>
###xml 830 834 <span type="species:ncbi:10090">mice</span>
###xml 863 867 <span type="species:ncbi:10090">mice</span>
###xml 1258 1262 <span type="species:ncbi:10090">mice</span>
###xml 1337 1341 <span type="species:ncbi:10090">mice</span>
###xml 1538 1543 <span type="species:ncbi:10090">mouse</span>
###xml 1607 1611 <span type="species:ncbi:10090">mice</span>
(a) 5x106 HuD p321-specific in vitro stimulated CD8+ T cells were adoptively transferred into Rag-/- mice (n = 2) with 2x106 C57BL/6 DC pulsed with p321. Mice also received PTx and IL-2. Eight days post transfer, mice were injected with CFSE-labeled syngeneic splenocytes pulsed with HuD p321 (CFSEhi) or betagal p96 (CFSElo). A naive control mouse without transferred CD8+ T cells was injected with CFSE-labeled splenocytes. 6 hours after target injection, splenocytes were analyzed by FACS for in vivo target cell lysis. A representative mouse is shown. Data is representative of two experiments. (b) C57BL/6 mice (n = 2) were used as recipients of adoptively transferred HuD p321-specific CD8+ T cells as in (a). A representative mouse is shown. Data is representative of two experiments. (c) Primary kidney cells from C57BL/6 mice (Db+/Kb+) or transgenic Bm1 mice (Db+/Kb-) were irradiated and pulsed with HuD p321 or betagal p96 and used as stimulators in an IFNgamma ELIPOST assay (5x104/well) with 3x restimulated HuD p321-specific or betagal p96-specific CD8+ T cells (104/well). The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean. Data is representative of two experiments. (d) C57BL/6 mice were immunized with either AdVHuD or influenza virus or left untreated (2 mice per group). 15 days after immunization, CD8+ T cells were isolated from the spleen and stained directly ex vivo with anti-CD8+ antibody and PE-labeled tetramer. A portion of splenocytes from each mouse was stimulated in vitro with cognate peptide for 7 days. Naive mice were stimulated with HuD p321. CD8+ T cells from in vitro stimulation cultures were stained with anti-CD8+ antibody and PE-labeled tetramer. Plots are gated on CD8+ T cells. Data is representative of two experiments.
###end p 42
###begin p 43
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 279 282 279 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bm1</sup>
###xml 336 337 336 337 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 421 424 421 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bm1</sup>
###xml 460 466 460 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig 2c</xref>
###xml 567 570 564 567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bm1</sup>
###xml 632 633 629 630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 695 696 692 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 283 288 <span type="species:ncbi:10090">mouse</span>
We defined the MHC restriction of HuD p321-specific CD8 T cells in order to design tetramers able to bind their T cell receptors. p321 was predicted to bind Db MHC I on the basis of its amino acid sequence (). To formally assess the MHC I restriction, we took advantage of the H2bm1 mouse strain, which expresses a mutated form of the Kb allele. HuD p321-specific CD8 T cells were able to respond to both wild type and H2bm1 cells pulsed with cognate peptide (Fig 2c). In contrast, beta-galp96-specific CD8 T cells recognized peptide-pulsed wild type cells but not H2bm1 cells pulsed with cognate peptide, since the p96 epitope is Kb-restricted. These results confirm that p321 is presented on Db MHC I.
###end p 43
###begin p 44
###xml 33 34 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 109 116 109 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig. 2d</xref>
###xml 383 384 383 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 617 625 617 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 647 653 647 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig 2d</xref>
###xml 942 949 936 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1049 1057 1043 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1101 1107 1095 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g002">Fig 2d</xref>
###xml 1188 1195 1182 1189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1242 1250 1236 1244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1491 1498 1485 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1514 1522 1508 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1580 1587 1574 1581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 251 255 <span type="species:ncbi:10090">mice</span>
We were then able to generate a Db-p321 tetramer that bound to HuD-specific CD8+ T cells (data not show, and Fig. 2d). We used this tetramer to monitor the expansion of HuD-specific CD8+ T cells after immunization with adenovirus-HuD. For comparison, mice were immunized with influenza virus to track the expansion of NP-specific CD8+ T cells (NP is an influenza epitope that binds Db MHC I). When we measured the frequency of NP-specific CD8+ T cells directly ex vivo, we observed an expected frequency of NP-specific T cells (1.5% of the total CD8+ T cell repertoire), and this population was further expanded upon in vitro stimulation with NP (Fig 2d). We also found a similar degree of expansion of beta-gal-specific CD8+ T cells directly after immunization with adenovirus-beta-gal (data not shown). In contrast, after immunization with adenovirus-HuD we saw almost no detectable proliferation of HuD p321-specific CD8+ T cells directly ex vivo. Strikingly, however, we were able to expand the population of HuD p321-specific CD8+ T cells upon in vitro stimulation to 1.4% of total CD8+ T cells (Fig 2d). The proliferation of HuD-specific T cells depended on the presence of antigen in vivo, since naive splenocytes did not expand after in vitro stimulation with p321. Thus, T cells specific for the neuronal antigen HuD do not respond to antigen in a similar manner as T cells specific for a neoantigen; after immunization with adenovirus-HuD, CD8+ T cells are not detectable directly ex vivo, but are after in vitro expansion, suggesting that their expansion is suppressed in vivo.
###end p 44
###begin title 45
Pertussis toxin and in vitro stimulation are required for HuD-specific CD8+ T activation
###end title 45
###begin p 46
###xml 121 128 117 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 371 378 360 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 581 588 556 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 649 656 624 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g003">Fig. 3a</xref>
###xml 718 726 693 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 765 772 736 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g003">Fig. 3b</xref>
###xml 834 841 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 960 968 927 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1114 1122 1081 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1309 1317 1276 1284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 130 134 <span type="species:ncbi:10090">Mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 1001 1005 <span type="species:ncbi:10090">mice</span>
###xml 1197 1201 <span type="species:ncbi:10090">mice</span>
To assess the functional status of HuD-specific CD8+ T cells we compared their ability to produce IFNgamma after priming in vivo. Mice were immunized with adenovirus-HuD or adenovirus-beta-gal in combination with pertussis toxin, which was used as an adjuvant to boost the HuD-specific T cell response, and CD8+ T cell IFNgamma secretion activation was measured directly ex vivo. After immunization with adenovirus-beta-gal we saw robust IFNgamma secretion by beta-gal p96-specific CD8+ T cells. In contrast, we saw no IFNgamma secretion by HuD p321-specific CD8+ T cells directly ex vivo after immunization with adenovirus-HuD and pertussis toxin (Fig. 3a). When splenocytes from these immunized mice were stimulated in vitro, we then detected IFNgamma secretion (Fig. 3b), indicating that these cells were able to recognize antigen in vivo, but were prevented from becoming effector cytotoxic T cells. Interestingly, no IFNgamma secretion was detected after in vitro stimulation of splenocytes from mice immunized with adenovirus-HuD in the absence of pertussis toxin. The dependence on both pertussis toxin and in vitro stimulation for the activation of HuD-specific CD8+ T cells suggests that mice may be tolerized to the HuD protein since their activation requires both additional adjuvant and expansion in vitro.
###end p 46
###begin title 47
###xml 8 12 <span type="species:ncbi:10090">mice</span>
C57BL/6 mice are tolerized to HuD.
###end title 47
###begin p 48
###xml 185 186 178 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 233 234 226 227 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 514 522 507 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 612 613 601 602 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 659 660 648 649 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 843 846 832 835 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 853 856 842 845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1178 1186 1163 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1305 1306 1286 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1348 1349 1329 1330 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 413 417 <span type="species:ncbi:10090">mice</span>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
###xml 857 861 <span type="species:ncbi:10090">mice</span>
###xml 1140 1144 <span type="species:ncbi:10090">mice</span>
(a) C57BL/6 mice were immunized with AdVHuD or AdVbetagal+PTx (2 mice per group). 13 days later, CD8+ T cells were isolated from the spleen and plated in an IFNgamma ELISPOT assay (2x105/well) with EL4 pulsed with 10 uM peptide (5x104/well). The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean. Data is representative of four experiments. (b) C57BL/6 mice were immunized with AdVHuD-/+PTx (2 mice per group). 13 days later, splenocytes were stimulated in vitro with 0.5 uM HuD p321. On day 7, CD8+ T cells were plated in an IFNgamma ELISPOT assay (104/well) with DC pulsed with 10 uM peptide (7x103/well). The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean Data is representative of two experiments. (c) Individual HuD+/+ or HuD-/- mice were immunized with AdVHuD+PTx and used in an IFNgamma ELISPOT assay as described in (a). The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean. Data is representative of four experiments. (d) Half of the spleens from mice immunized in (c) were stimulated in vitro with HuD p321. After 7 days, CD8+ T cells were isolate from stimulation cultures and plated in an IFNgamma ELISPOT (104/well) with peptide pulsed EL4 cells (5x104/well).
###end p 48
###begin title 49
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice are tolerized to HuD
###end title 49
###begin p 50
###xml 63 67 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Akamatsu1">[24]</xref>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 106 109 106 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 229 236 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 249 252 245 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 339 342 335 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 414 421 410 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 423 429 419 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g003">Fig 3c</xref>
###xml 465 472 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 488 491 484 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 557 565 553 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 669 675 665 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g003">Fig 3d</xref>
###xml 711 718 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 910 918 906 914 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 253 257 <span type="species:ncbi:10090">mice</span>
###xml 343 347 <span type="species:ncbi:10090">mice</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 751 755 <span type="species:ncbi:10090">mice</span>
###xml 971 975 <span type="species:ncbi:10090">mice</span>
To assay for tolerance to HuD, we immunized HuD-deficient mice [24] (HuD-/-) or wild-type littermates (HuD+/+) with adenovirus-HuD plus pertussis toxin and looked for IFNgamma secretion by HuD p321-specific CD8+ T cells directly ex vivo. Whereas HuD+/+ mice were unable to generate activated HuD p321-specific cells after immunization, HuD-/- mice generated strong HuD p321-specific CD8+ T cell responses directly ex vivo (Fig 3c). To assess whether the lack of an ex vivo response in HuD+/+ mice was due to ineffective immunization, splenocytes stimulated in vitro with p321 were assayed and found to be competent to generate activated HuD p321-specific CD8+ T cells (Fig 3d). The ability to prime this robust ex vivo HuD-specific T cell response in mice lacking the HuD antigen, in contrast with the inability of wild-type animals to activate HuD-specific CD8+ T cells in the absence of pertussis toxin plus in vitro stimulation, supports the conclusion that wild-type mice are tolerized to the neuronal antigen HuD.
###end p 50
###begin p 51
###xml 233 239 233 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g004">Fig 4a</xref>
###xml 540 546 540 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g004">Fig 4b</xref>
###xml 634 635 634 635 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 754 755 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 1087 1093 1079 1085 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005739-g004">Fig 4c</xref>
###xml 789 793 <span type="species:ncbi:10090">mice</span>
We compared the CD8+ T cell response to HuD and HuA, a closely related Hu-family member that is expressed ubiquitously throughout the body. In the p321 region of the two proteins, HuA differs from HuD at a single amino acid residue (Fig 4a), although the anchor residues that stabilize the peptide-MHC interaction are conserved between the two peptides, suggesting that they might bind MHC I with similar affinity. We tested the affinities of HuA p321 versus HuD p321 for MHC I using RMA/S cells incubated with serial dilutions of peptide (Fig 4b). HuA p321 had a higher avidity for Db MHC I compared to HuD p321, and HuD p321 bound Db with similar affinity to the control peptide NP. To determine if HuA p321-specific CD8+ T cells are present in the H-2b repertoire, we immunized C57BL/6 mice with peptide emulsified in TiterMax and looked seven days later for IFNgamma secretion by CD8+ T cells plated with peptide-pulsed stimulators. Whereas both HuD p321-specific T cells and NP-specific T cells were detectable by IFNgamma secretion, no HuA p321-specific T cells could be detected (Fig 4c). These results suggest that T cells specific to the peripheral HuA protein have been deleted from the repertoire or are subject to a more complete and irreversible form of tolerance relative to HuD-specific T cells. Conversely, the ability to detect HuD p321-specific CD8+ T cells confirms that these cells are not deleted by a central tolerance mechanism.
###end p 51
###begin title 52
Comparison of HuA p321-specific CD8+ T cells and HuD p321-specific CD8+ T cells.
###end title 52
###begin p 53
###xml 120 121 120 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 516 517 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 559 560 555 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 309 313 <span type="species:ncbi:10090">mice</span>
###xml 406 410 <span type="species:ncbi:10090">mice</span>
(a) Sequences of HuD p321 and HuA p321 (b) RMA/S cells were incubated with serial dilutions of peptide and stained for Db MHC I. HuD p321 and HuA p321 were assayed. The A2.1 epitope of influenza (M1) was used as a negative control. The Db epitope of influenza (NP) was used as a positive control. (c) C57BL/6 mice were immunized with individual peptides (NP, HuA p321, or HuD p321) in TiterMax adjuvant (2 mice per group). 7 days later, draining lymph node CD8+ T cells were plated in an IFNgamma ELISPOT assay (2x105/well) with peptide pulsed EL4 cells (5x104/well). The assay was performed in triplicate. Means are plotted and error bars represent standard deviations of the mean. Data is representative of four experiments.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 791 795 779 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Darnell3">[27]</xref>
###xml 1133 1136 1121 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Carson1">[3]</xref>
###xml 1138 1141 1126 1129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Galea2">[5]</xref>
###xml 1143 1147 1131 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Neumann1">[28]</xref>
###xml 1149 1153 1137 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Ransohoff1">[29]</xref>
###xml 1500 1507 1488 1495 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex vivo</italic>
###xml 1530 1538 1518 1526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 236 244 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 840 848 <span type="species:ncbi:9606">patients</span>
###xml 1368 1372 <span type="species:ncbi:10090">mice</span>
###xml 1435 1439 <span type="species:ncbi:10090">mice</span>
###xml 1610 1614 <span type="species:ncbi:10090">mice</span>
Autoimmune attack against neurons is particularly detrimental, since neurons have limited capacity for regeneration and damage may therefore be permanent. This is clearly the case in the PNDs, where the clinical outcome in these cancer patients is typically determined by the neurologic disease. In the severest forms of the Hu syndrome, patients survive an average of only 7 months from the onset of their illness. Dogma in the past approximately60 years has been that the immune system is ignorant to neuron-specific proteins such as the Hu antigen. However, it has become clear that the HuD antigen, as well as other PND antigens, may be commonly expressed outside of neurons in common cancer types (all small cell lung cancers express HuD, and over half of ovarian cancers express cdr2) [27]. Although only rare subsets of these cancer patients ever develop PND, it would seem that reliance on ignorance of neuronal proteins would pose a potentially great immunologic risk, as neurons induce MHC I molecules during inflammation, at the same time that activated T cells are allowed entry to the CNS across the blood brain barrier [3], [5], [28], [29]. In setting out here to look for HuD-specific T cell responses we have discovered an unexpected resolution to these conflicting points by finding that there is strong tolerance to the HuD protein in normal resting mice. Tolerance to HuD was confirmed by finding that HuD-deficient mice generate functional HuD p321-specific CD8+ T cells directly ex vivo, without the need for in vitro stimulation with peptide. This tolerance was functionally relevant, as mice examined after receiving HuD immunizations or at various times after HuD CD8+ T cell adoptive transfer (9 days, 18 days, one month) did not develop evidence of neurologic dysfunction or abnormalities evident by immunohistochemical studies of brain sections.
###end p 55
###begin p 56
###xml 57 58 57 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 370 374 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Okano1">[30]</xref>
###xml 436 440 436 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Derbinski1">[31]</xref>
###xml 1324 1326 1320 1322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1578 1580 1571 1573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;9</sup>
###xml 273 278 <span type="species:ncbi:10090">mouse</span>
###xml 476 480 <span type="species:ncbi:10090">mice</span>
###xml 989 997 <span type="species:ncbi:9606">patients</span>
###xml 1656 1660 <span type="species:ncbi:10090">mice</span>
The presence of HuD p321-specific CD8+ T cells in the H-2b repertoire indicates that these cells are either not subject to central tolerance induction in the thymus, or exist as a result of incomplete central tolerance. Extensive examination of HuD expression in the adult mouse has failed to find protein in the thymus or any other tissue outside of the nervous system [30], and HuD does not appear to be regulated by the AIRE protein [31]. In addition, we immunized AIRE KO mice with adenovirus-HuD and saw no HuD p321 specific T cell directly ex vivo (data not shown). In contrast, when we compared the CD8+ T cell response to HuD p321 versus its homologous epitope in HuA, we found that HuA p321-specific CD8+ T cells were not detected after TiterMax immunization, suggesting that they were centrally deleted. Given HuA's ubiquitous expression pattern, central tolerance would be important to prevent the development of widespread peripheral autoimmunity, which is not observed in HuD patients. In contrast, HuD p321-specific CD8+ T cells were present in the repertoire; moreover, the IFNgamma response of HuD p321-specific T cells was comparable in magnitude to that elicited from neoantigen-specific T cells after Titermax-peptide immunization. While this experiment was done with a high concentration of peptide (1x10-5 M), which could have obscured low affinity T cell responses, we found that the affinity of restimulated HuD and betagal T cells were comparable (in peptide ELISPOT titration assays, both recognized targets pulsed with dilutions of peptide down to 1x10-9 M; data not shown). Taken together, our data point to the possibility that mice normally have a mechanism for maintaining active tolerance to a neuron-specific protein.
###end p 56
###begin p 57
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Okano1">[30]</xref>
###xml 942 946 942 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Lee1">[32]</xref>
###xml 602 607 <span type="species:ncbi:10090">mouse</span>
###xml 967 972 <span type="species:ncbi:10090">mouse</span>
The maintenance of tolerance, either by regulatory T cells or through induction of anergy of CD8+ T cells in the periphery, requires a means for antigen to be captured and presented to antigen presenting cells (APCs), which themselves make no detectable HuD mRNA (unpublished data). Given the restricted expression of HuD to neurons, which do not turnover in the steady state, the means of sustaining peripheral tolerance to HuD would seem dependent on either ectopic expression of the protein by a non-neuronal cell type, or cross presentation of HuD by an APC. Examination of HuD expression in adult mouse tissue has confirmed its restriction to neurons [30] (Darnell et al., unpublished data), although it is difficult to exclude the possibility that an undetectable amount of protein may have escaped detection in these negative results. Recently, ectopic expression of peripheral-tissue antigens by lymph node stromal cells was reported [32]. In this transgenic mouse model, a cytosolic form of ovalbumin (OVA) under the control of a tissue-specific promoter was shown to be endogenously processed and presented onto MHC I molecules by a stromal cell population in the lymph node cortex. Endogenous presentation of OVA in the lymph node was an effective means of inducing tolerance in naive OT-I CD8+ T cells. Circulating HuD-specific CD8+ T cells may be subject to a similar form of regulation if ectopic expression of HuD by lymph node cells resulted in presentation of HuD p321 peptide complexes, although we have no expression data to support such a speculation.
###end p 57
###begin p 58
###xml 205 208 205 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Galea1">[2]</xref>
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Ransohoff1">[29]</xref>
###xml 216 220 216 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-deVos1">[33]</xref>
###xml 222 226 222 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Karman1">[34]</xref>
###xml 825 829 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Albert1">[18]</xref>
###xml 831 835 831 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Albert2">[35]</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Banerjee1">[36]</xref>
###xml 1025 1029 1025 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Streilein1">[37]</xref>
Soluble CNS antigens may drain to cervical lymph nodes, and proteins in the CNS can readily access lymphoid tissues via the CSF and cervical lymphatics for processing and presentation to the immune system [2], [29], [33], [34]. However, it is not clear that this pathway is relevant to an intracellular neuronal protein like HuD. Another possibility is that phagocytosis of HuD-expressing neurons, or fragments of neurons such as remodeling synapses, could provide a means for antigen entry into an APC. While whole neurons may not be a likely form of antigen for APCs given their limited ability to turn-over, APCs may be able to phagocytose membrane-bound neuronal blebs for cross presentation and subsequent tolerance induction, in a manner analogous to their general ability to cross-present antigen from apoptotic cells [18], [35]. For example, outer segments of photoreceptors, normally phagocytosed by retinal pigment epithelium, may instead be phagocytosed by microglia following transplantation into the brain [36], [37].
###end p 58
###begin p 59
###xml 665 669 665 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005739-Heath1">[38]</xref>
###xml 361 369 <span type="species:ncbi:9606">patients</span>
We have shown that a protein confined in expression to neurons is not ignored by the immune system but undergoes tolerance induction in order to prevent against autoimmunity directed at the nervous system. The maintenance of tolerance to HuD is apparently quite effective, given that all SCLC express the HuD antigen but only a very small (0.01%) population of patients succumbs to neuronal degeneration. Tolerance to HuD suggests revisiting the model of the brain as an immune privileged organ. Rather, we suggest the opposite possibility, that there exists a natural mechanism that acts in the steady state, similar to what occurs with peripheral tissue antigens [38], but that is perhaps even more profound, to tolerize T cells to brain antigens as a default, and for the same end purpose-to keep the organ from autoimmune attack. In this context, Medawar's data and follow-up studies may be explained by immunologic tolerance to brain antigens, even newly transplanted antigens, rather than by immunologic ignorance as originally suggested.
###end p 59
###begin p 60
###xml 195 199 <span type="species:ncbi:10090">mice</span>
We thank members of the laboratory and Matthew Albert for helpful discussions and critical review of the work. We are grateful to Hideyoki Okano and Hirotaka James Okano for sharing the HuD null mice.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
Immunity to homologous grafted skin. III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye.
###end article-title 62
###begin article-title 63
What is immune privilege (not)?
###end article-title 63
###begin article-title 64
CNS immune privilege: hiding in plain sight.
###end article-title 64
###begin article-title 65
Basic principles of immunological surveillance of the normal central nervous system.
###end article-title 65
###begin article-title 66
An antigen-specific pathway for CD8 T cells across the blood-brain barrier.
###end article-title 66
###begin article-title 67
Myelin basic protein infused into cerebrospinal fluid suppresses experimental autoimmune encephalomyelitis.
###end article-title 67
###begin article-title 68
Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation.
###end article-title 68
###begin article-title 69
###xml 22 30 <span type="species:ncbi:9606">patients</span>
Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.
###end article-title 69
###begin article-title 70
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.
###end article-title 70
###begin article-title 71
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer-a quantitative western blot analysis.
###end article-title 71
###begin article-title 72
Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites.
###end article-title 72
###begin article-title 73
Demonstration of serum anti-Purkinje antibody in paraneoplastic cerebellar degeneration and preliminary antigenic characterization.
###end article-title 73
###begin article-title 74
Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity and the brain.
###end article-title 74
###begin article-title 75
Paraneoplastic syndromes involving the nervous system.
###end article-title 75
###begin article-title 76
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies.
###end article-title 76
###begin article-title 77
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis.
###end article-title 77
###begin article-title 78
###xml 54 59 <span type="species:ncbi:9606">human</span>
A T-cell receptor associated with naturally occurring human tumor immunity.
###end article-title 78
###begin article-title 79
Tumor-specific killer cells in paraneoplastic cerebellar degeneration.
###end article-title 79
###begin article-title 80
###xml 57 65 <span type="species:ncbi:9606">patients</span>
No evidence for circulating HuD-specific CD8+ T cells in patients with paraneoplastic neurological syndromes and Hu antibodies.
###end article-title 80
###begin article-title 81
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
###xml 97 102 <span type="species:ncbi:9606">human</span>
Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human.
###end article-title 81
###begin article-title 82
###xml 36 44 <span type="species:ncbi:9606">patients</span>
T cell response to Hu-D peptides in patients with anti-Hu syndrome.
###end article-title 82
###begin article-title 83
Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome.
###end article-title 83
###begin article-title 84
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients with lung cancer and the paraneoplastic Hu syndrome harbor HuD-specific Type 2 CD8+ T cells.
###end article-title 84
###begin article-title 85
The RNA-binding protein HuD regulates neuronal cell identity and maturation.
###end article-title 85
###begin article-title 86
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.
###end article-title 86
###begin article-title 87
T cell receptor (TCR) recognition of MHC class I variants: intermolecular second-site reversion provides evidence for peptide/MHC conformational variation.
###end article-title 87
###begin article-title 88
###xml 45 50 <span type="species:ncbi:9606">human</span>
cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors.
###end article-title 88
###begin article-title 89
Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha.
###end article-title 89
###begin article-title 90
Three or more routes for leukocyte migration into the central nervous system.
###end article-title 90
###begin article-title 91
A hierarchy of Hu RNA binding proteins in developing and adult neurons.
###end article-title 91
###begin article-title 92
Promiscuous gene expression in thymic epithelial cells is regulated at multiple levels.
###end article-title 92
###begin article-title 93
Peripheral antigen display by lymph node stroma promotes T cell tolerance to intestinal self.
###end article-title 93
###begin article-title 94
Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs.
###end article-title 94
###begin article-title 95
Initiation of immune responses in brain is promoted by local dendritic cells.
###end article-title 95
###begin article-title 96
Dendritic cells acquire antigen from apoptotic cells and induce class I- restricted CTLs.
###end article-title 96
###begin article-title 97
A role for microglia in the maintenance of photoreceptors in retinal transplants lacking pigment epithelium.
###end article-title 97
###begin article-title 98
Immunobiology and privilege of neuronal retina and pigment epithelium transplants.
###end article-title 98
###begin article-title 99
Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens.
###end article-title 99
###begin p 100
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 100
###begin p 101
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by the NIH (R01 CA85784 to RBD), the Howard Hughes Medical Institute, and the Rockefeller University Hospital CTSA Grant (UL1 RR024143) from the National Center for Research Resources at the National Institutes of Health. RBD is an Investigator of the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 101

